Figure 4 | Scientific Reports

Figure 4

From: Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options

Figure 4

Parental HER2+ and transformed resistant cells respond uniquely to therapy in vitro.

MTS proliferation assay (Promega) was carried out after incubating cell lines with increasing concentration of SF for 72 hours. (A) PTEN knock down and long term trastuzumab (LTT) culture with HER2 amplified BT474 sensitizes the cell line to SF. (B) MTS assay performed in triple negative SUM159, SUM 159 with shPTEN, SUM159 with HER2 over expression and SUM159 shPTEN with HER2 overexpression. (C) Model of SF efficacy demonstrating cell lines with HER2 amplification in the absence of PTEN deletion are likely to be insensitive to SF treatment whereas deletion of PTEN is likely to enhance efficacy. (A,B) N = 6. Data are shown as averages ± SD.

Back to article page